Hikma Pharmaceuticals Plc Stock Shares Outstanding
HKMPY Stock | USD 46.50 0.00 0.00% |
Hikma Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Hikma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Hikma Pink Sheet. The fundamental analysis module provides a way to measure Hikma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hikma Pharmaceuticals pink sheet.
Hikma |
Hikma Pharmaceuticals PLC Company Shares Outstanding Analysis
Hikma Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Hikma Pharmaceuticals Shares Outstanding | 110.13 M |
Most of Hikma Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hikma Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Based on the latest financial disclosure, Hikma Pharmaceuticals PLC has 110.13 M of shares currently outstending. This is 39.0% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all United States stocks is 80.74% higher than that of the company.
Hikma Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hikma Pharmaceuticals' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hikma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Hikma Pharmaceuticals by comparing valuation metrics of similar companies.Hikma Pharmaceuticals is currently under evaluation in shares outstanding category among related companies.
Hikma Fundamentals
Return On Equity | 0.15 | |||
Return On Asset | 0.077 | |||
Profit Margin | 0.14 % | |||
Operating Margin | 0.22 % | |||
Current Valuation | 5.26 B | |||
Shares Outstanding | 110.13 M | |||
Price To Earning | 10.10 X | |||
Price To Book | 1.89 X | |||
Price To Sales | 1.60 X | |||
Revenue | 2.55 B | |||
Gross Profit | 1.3 B | |||
EBITDA | 759 M | |||
Net Income | 421 M | |||
Cash And Equivalents | 393 M | |||
Cash Per Share | 3.57 X | |||
Total Debt | 651 M | |||
Debt To Equity | 0.71 % | |||
Current Ratio | 2.12 X | |||
Book Value Per Share | 19.77 X | |||
Cash Flow From Operations | 638 M | |||
Earnings Per Share | 2.99 X | |||
Price To Earnings To Growth | 2.41 X | |||
Number Of Employees | 8.7 K | |||
Beta | 0.35 | |||
Market Capitalization | 4.72 B | |||
Total Asset | 4.37 B | |||
Retained Earnings | 1.16 B | |||
Working Capital | 701 M | |||
Current Asset | 1.57 B | |||
Current Liabilities | 866 M | |||
Z Score | 4.2 | |||
Annual Yield | 0.03 % | |||
Five Year Return | 1.79 % | |||
Net Asset | 4.37 B | |||
Last Dividend Paid | 0.55 |
About Hikma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hikma Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hikma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hikma Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hikma Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hikma Pharmaceuticals' short interest history, or implied volatility extrapolated from Hikma Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hikma Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Hikma Pink Sheet analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |